(Total Views: 303)
Posted On: 02/01/2022 8:26:14 PM
Post# of 30015
![Avatar](https://investorshangout.com/images/ProfileImages/1996739806_13310_Entertained 3.jpg)
In looking up small trials and very large trials that are Covid related, the ones I see are on top of SOC. Are there ones where patients don't get SOC? I don't know, but I wouldn't participate unless I did.
Galecto is about the size of Todos. Their stock went from $15 to $2 something. Maybe JP was trying to warn everyone there too as there can't possibly two dumbass morons that try to impede life saving treatments because they got way over their heads with pumping OTC stocks and have no self-awareness.
Galecto Publishes Results Showing Safety and Efficacy of the GB0139 Inhaled Galectin-3 Inhibitor in Hospitalized COVID-19 Patients on Standard of Care
"The study showed that GB0139 on top of standard of care (which included treatments such as steroids, heparin, remdesivir and tocilizumab) may rapidly decrease markers of inflammation linked to the cytokine storm, inflammation-associated micro-thrombosis and those of short or long-term fibrosis."
https://finance.yahoo.com/news/galecto-publis...00995.html
WHO COVID-19 Solidarity Therapeutics Trial
"The WHO Solidarity PLUS Trial will initially evaluate three treatment arms: artesunate, infliximab and imatinib, in addition to the local standard of care ."
https://www.who.int/emergencies/diseases/nove...treatments
Galecto is about the size of Todos. Their stock went from $15 to $2 something. Maybe JP was trying to warn everyone there too as there can't possibly two dumbass morons that try to impede life saving treatments because they got way over their heads with pumping OTC stocks and have no self-awareness.
Galecto Publishes Results Showing Safety and Efficacy of the GB0139 Inhaled Galectin-3 Inhibitor in Hospitalized COVID-19 Patients on Standard of Care
"The study showed that GB0139 on top of standard of care (which included treatments such as steroids, heparin, remdesivir and tocilizumab) may rapidly decrease markers of inflammation linked to the cytokine storm, inflammation-associated micro-thrombosis and those of short or long-term fibrosis."
https://finance.yahoo.com/news/galecto-publis...00995.html
WHO COVID-19 Solidarity Therapeutics Trial
"The WHO Solidarity PLUS Trial will initially evaluate three treatment arms: artesunate, infliximab and imatinib, in addition to the local standard of care ."
https://www.who.int/emergencies/diseases/nove...treatments
![](/m/images/thumb-up.png)
![](/m/images/thumb-down.png)